Titlebook: Adjuvant Therapy of Breast Cancer IV; Hans-Jörg Senn,Richard D. Gelber,Beat Thürlimann Conference proceedings 1993 Springer-Verlag Berlin

Melodrama

Uffe B. Kjærulff,Anders L. Madsental survival rates over those recently achieved with systemic adjuvant treatments [2, 5, 6] (the latter of these is reprinted in part in this volume). This paper summarizes and updates the clinical results of the prospective trial started in 1988 at the Milan Cancer Institute [7].

谄媚于性

关节炎

Spirometry

Conference proceedings 1993ality of care for breast cancer patients. Clinical investigations and clinical trials have made the largest contribution to the body of knowledge that finds its way to the patient. Never before during the past decades of management of breast cancer has there been such a fruitful intellectual cross-f

Spinal-Fusion

Learning the Structure of Bayesian Networksl decades [1]. Although most patients’ tumors respond to modern high-dose chemotherapies, median survival times have advanced by mere months [2]. Indeed, prolongation of life to the length of a “natural”lifespan . cancer is rarely achieved. Even ultrahigh-dose chemotherapy with autologous bone marro

Limited

Information Science and Statisticsrating, self-renewing stem cells, (b) proliferating, non-self-renewing (transitional) cells and (c) non-proliferating, differentiated (end) cells. In 1984 we introduced the concept of two subpopulations of tumor stem cells (TSC; Fig. 1) [1]. One of these we refer to as the primitive or ancestral TSC

braggadocio

Efflorescent

Information Science and Statisticstifertility agent. It was found, however, that tamoxifen actually induces ovulation in subfertile women. The antitumor effects of tamoxifen were more promising. The drug first entered clinical trials in the United Kingdom in 1971 [2] and was approved for use in the United States in 1978. It was init

破裂

Fecal-Impaction